Acuity3D: Acuity3d is a smart decision platform that uses AI to guide sales teams to take the right actions at the right time, increasing sales and revenue. Integrated into Salesforce, it assists in managing processes like prospecting, leads, and upselling.
Orum: Orum is an AI-powered platform designed to enhance sales activities, streamline team connections, and boost revenue. It facilitates live conversations to supercharge business operations.
Introducing Acuity3D and Orum
Acuity3D belong to a category of solutions that help Sales Engagement, whereas Orum belong to a category of solutions that help Auto Dialer. Different products excel in different areas, so the best platform for your business will depend on your specific needs and requirements.
Acuity3D covers Engagement Management, Lead Engagement, Workflow Management with E-Mail, Lead Qualification, etc.
Orum focuses on Telemarketing with Phone Calls, Workflow Management with Phone Calls, Contact List Management with Phone Calls, Communication Management.
Unsure which of these solutions is right for you? Our Cuspera AI engine can compare them based on your needs and specific to your industry and context. Get your personalized report today.
Acuity3D and Orum: Best activities based on customer satisfaction
Top Processes
Customer evidence for the processes each product supports. Click Read Reviews to open peer feedback.
Evidences indicate better relative satisfaction
Top Goals
Goals Achieved
-
Acquire customers
-
Shorten ramp up time
-
Increase sales & revenue
IT and Other Capabilities
- Low
- Medium
- High
Data
Support
Others
Business Setting
Acuity3D peer evidence is 100% Enterprise. Orum peer evidence is 100% SMB and Mid-Market.
| Acuity3D | Orum | |
|---|---|---|
| Peer score | 4.0 | 3.9 |
| Peer insights | 54 | 18 |
| Top industries |
Computer Software 52.0%
Information Technology And Services 48.0%
|
|
| SMB and Mid-Market | 0.0% | 100.0% |
| Enterprise | 100.0% | 0.0% |
| Pricing | Acuity3D |
News
Latest Orum news
BrisÂtol MyÂers scraps $100M Orum canÂcer drug afÂter reÂviewÂing Phase 1 daÂta
Bristol Myers Squibb has terminated the development of a cancer drug, BMS-986497/ORM-6151, which was co-developed with Orum, following a review of Phase 1 data.